Boehringer In­gel­heim boosts R&D com­mit­ment, promis­es up to 15 new prod­uct launch­es by 2025

4 years ago
R&D
Pharma

Sen­a­tors grill in­dus­try groups over FDA user fee agree­ments to fund the agency through 2027

4 years ago
FDA+

Sen­a­tors call on HHS to in­ves­ti­gate McK­in­sey's al­leged ties with FDA, opi­oid man­u­fac­tur­ers

4 years ago
Pharma
FDA+

What's go­ing on with Mer­ck­'s off­shore tax prac­tices as tax rate plunges to 11% and Sen­ate Fi­nance Chair Ron Wyden ...

4 years ago
Pharma

Mar­ket­ingRx roundup: Mer­ck re­ups HPV ads for young adults; Idor­sia study con­firms lit­tle sleep for weary

4 years ago
Pharma
Marketing

No­vo Nordisk trades Ry­bel­sus' an­i­mat­ed Covid-launch ads for ‘more re­lat­able’ live ac­tion cam­paign

4 years ago
Pharma
Marketing

Glax­o­SmithK­line keeps truck­ing along­side AI with new, mul­ti-year pathol­o­gy part­ner­ship with Boston out­fit

4 years ago
Deals
AI

PhI­Ib im­plo­sion punts Imara back to pre­clin­i­cal mode as biotech ax­es pro­grams in sick­le cell dis­ease, ...

4 years ago
R&D

David Saba­ti­ni re­signs MIT pro­fes­sor­ship af­ter sex­u­al ha­rass­ment probe led to ouster from White­head In­sti­tute

4 years ago
People

Who are the LGBTQ+ lead­ers forg­ing paths in bio­phar­ma in 2022? Nom­i­nate them for an End­points spe­cial re­port

4 years ago
People
R&D

Doug Melton to re­unite with his Sem­ma col­lab­o­ra­tors at Ver­tex to de­vel­op 'cu­ra­tive cell ther­a­pies'

4 years ago
People
Pharma

Spot­light­ing sub­group analy­sis, Ther­a­vance tries to carve out 'nar­row, but crit­i­cal­ly im­por­tan­t' mar­ket for failed ...

4 years ago
R&D

As­traZeneca and Io­n­is claim a PC­SK9 win, but will it mat­ter in a crowd­ed mar­ket?

4 years ago
R&D

Blue­bird joins the lay­off flock to re­al­i­ty as gene ther­a­py biotech sheds staff to save it­self

4 years ago
People
R&D

Covid-19 roundup: Con­gress agrees to $10B spend­ing bill; New preprint shows Gilead­'s Vek­lury is in­ef­fec­tive

4 years ago
Coronavirus

FDA con­venes com­mit­tee of vac­cine ex­perts to con­sid­er a flu-like path for Omi­cron-spe­cif­ic boost­ers

4 years ago
FDA+
Coronavirus

CDER chief calls for ad­di­tion­al bud­get funds as staff de­par­tures spiked last sum­mer

4 years ago
FDA+

AMR Ac­tion Fund looks to tack­le an­timi­cro­bial re­sis­tance with first two in­vest­ments — but does the mon­ey ar­rive too ...

4 years ago
Financing
Pharma

'About as true as say­ing the earth is flat': Alzheimer's ex­pert picks apart Bio­gen's Aduhelm man­u­script

4 years ago
People
R&D

Gilead­'s land­mark CAR-T ap­proval leaves Bris­tol My­ers Squibb scram­bling for sec­ond place

4 years ago
Pharma
Cell/Gene Tx

Pfiz­er, J&J, No­vo, Lil­ly and Sanofi among phar­ma TV ads jam­ming at Gram­my mu­sic awards

4 years ago
Pharma
Marketing

FDA tees up a snap re­view for Dupix­ent as Sanofi, Re­gen­eron hunt 4th ap­proval for megablock­buster

4 years ago
Pharma
FDA+

Af­ter steer­ing made-in-Chi­na CAR-T all the way from ob­scu­ri­ty to ap­proval, Frank Fan re­signs from Leg­end

4 years ago
People
China

Ned Sharp­less steps down as head of the Na­tion­al Can­cer In­sti­tute

4 years ago
People
FDA+
First page Previous page 545546547548549550551 Next page Last page
A service from the Financial Times